BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aptus Endosystems Inc. Receives CE Mark for the Aptus EndoStapling System


5/24/2011 6:50:33 AM

Aptus Endosystems, Inc., a medical device company developing advanced technology for endovascular aneurysm repair (EVAR), announced CE Mark approval for the Aptus EndoStapling System. The innovative helical staple technology enables independent endograft fixation, and is designed to mimic the hand suturing performed during open surgical repair of abdominal aortic aneurysms. Aortic aneurysms are an enlarged and weakened section of the aorta which can be lethal if left untreated. Each year, an estimated 100,000 people in Europe and about 200,000 people in the U.S. are diagnosed with this condition. In EVAR, an alternative to open surgical repair, a metal and fabric endograft is implanted using a catheter-based delivery system to isolate blood flow away from the aneurysm to prevent potential rupture and death.

The EndoStapling System provides physicians with a novel technology to repair endovascular grafts that have exhibited migration or endoleaks (or are at risk of these complications which are commonly seen after EVAR) where augmented radial fixation and/or sealing is required to regain or maintain effective aortic aneurysm exclusion. The system also can be used during de novo EVAR procedures (at the time of initial endograft implantation) to enhance an endograft’s inherent fixation and sealing mechanisms.

“The use of the Aptus EndoStapling system will be a great advantage to simplify revision surgery for migrated endografts,” said Jean Paul de Vries, M.D., Ph.D., Head of the Department of Vascular Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands. “The ability to staple migrated endografts to the aortic wall and to fixate extension cuffs will overcome most migrations and type IA endoleaks. This system truly mimics a sutured anastomosis.”

In addition, de Vries said, “EndoStaples can improve fixation of de novo endografts in challenging proximal necks – short, large and angulated – and can potentially reduce distal migration during follow-up.”

“We found the system to be a highly sophisticated, user friendly device, designed to be applied easily by the average user, requiring a short learning curve,” said Theodossios Perdikides, M.D., Director of Vascular Surgery, Hellenic Air Force Hospital, Athens, Greece “I believe this innovative technology promises to prevent or repair major EVAR-related pitfalls that can lead to failure or even disaster.”

“This is a big leap forward concerning minimally invasive bail-out for endografts at risk for migration,” said Joerg Tessarek, M.D., Chief of Vascular Surgery, St. Bonifatius Hospital, Lingen, Germany. “Not only for traditional infrarenal devices, but also for complex fenestrated or branched grafts where migration affects target vessel patency, this will be a helpful tool to provide graft stability.”

Aptus Endosystems CEO Jeff Elkins called the CE Mark approval a “significant milestone.” He went on to comment that, “Given the recent publication of several long term EVAR outcome studies, we now recognize that late EVAR failure and the need for secondary intervention is a major underserved clinical need affecting many patients, and continued improvement in technology is required. To date, physicians have had limited prophylactic and treatment options for graft migration and Type I endoleaks. The novel concept of independent and physician controlled proximal fixation using the EndoStapling System is a considerable step toward addressing long term complications and making EVAR a more definitive solution for treating aortic aneurysms.”

In addition to use with the Aptus endograft (which received CE Mark approval in 2009), the Aptus EndoStapling system has received CE approval for use with the Cook Zenith, Gore Excluder, and Medtronic AneuRx, Endurant, and Talent endografts in both initial implant and secondary repair settings. Use with other endografts has not been evaluated.

About Aptus Endosystems, Inc.

Aptus Endosystems is a privately held medical technology company that has developed advanced technology for the endovascular treatment of aortic aneurysm disease. Founded in 2002, Aptus Endosystems has developed a unique endograft and endovascular stapling system delivered via standard catheter technology. The technology allows surgeons to treat abdominal aortic aneurysms through a minimally invasive approach while still providing the control of an open repair. The Aptus Endovascular AAA Repair System and the EndoStapling System bear the CE Mark for distribution in the European Union. These products are Investigational Use only in the United States. For more information, please visit www.aptusendosystems.com

Contact:

Aptus Endosystems, Inc. Media Contact: Jeff Elkins, CEO Ph: 408.530.9050 jelkins@aptusendo.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES